VolitionRx Limited (VNRX)
VolitionRx Limited is a multi-national epigenetics company focused on developing and commercializing blood tests for various cancers and diseases. Their Nu.Q platform aims to provide accessible and accurate diagnostic solutions.
Company Overview
VolitionRx pioneers accessible cancer diagnostics through its Nu.Q platform, offering innovative blood tests for early detection and monitoring of various diseases, positioning itself for growth in the expanding epigenetics market with a focus on veterinary applications and nucleosome profiling.
Investment Thesis
VolitionRx presents a compelling investment opportunity due to its innovative Nu.Q platform and focus on early cancer detection. The company's potential lies in the growing market for non-invasive diagnostic tools and the increasing adoption of epigenetics-based diagnostics. Key value drivers include the expansion of Nu.Q into new applications, such as veterinary diagnostics and immune system monitoring. Upcoming catalysts include regulatory approvals and commercial partnerships. With a gross margin of 100.0%, VolitionRx has the potential for significant profitability as revenue scales. Investors should consider the company's high beta of 1.30, indicating higher volatility compared to the market. The company's current P/E ratio of -1.16 reflects its current lack of profitability, but future growth could change this.
Key Highlights
- Gross Margin of 100.0% demonstrates the potential for high profitability as revenue scales.
- Market Cap of $0.02B indicates a small-cap company with significant growth potential.
- Beta of 1.30 suggests higher volatility compared to the market, which could lead to higher potential returns or losses.
- Focus on epigenetics and nucleosomics offers a differentiated approach to cancer diagnostics.
- Nu.Q Vet provides a unique entry point into the veterinary diagnostics market.
Competitors
Strengths
- Innovative Nu.Q platform for cancer diagnostics.
- Proprietary Nucleosomics technology.
- Potential for early cancer detection.
- Veterinary application with Nu.Q Vet.
Weaknesses
- Limited commercialization to date.
- Negative profit margin.
- High beta indicating high volatility.
- Reliance on a single technology platform.
Catalysts
- Upcoming: Regulatory approvals for Nu.Q in new markets.
- Ongoing: Expansion of commercial partnerships for Nu.Q Vet.
- Ongoing: Publication of clinical data supporting the effectiveness of Nu.Q.
- Upcoming: Development of new diagnostic applications for the Nucleosomics platform.
Risks
- Potential: Competition from established diagnostic companies with greater resources.
- Ongoing: Regulatory hurdles and delays in obtaining approvals for new products.
- Potential: Failure to achieve commercial success with Nu.Q.
- Ongoing: Dependence on securing additional funding to support research and development.
- Potential: Product liability claims.
Growth Opportunities
- Expansion of Nu.Q into new cancer types: VolitionRx has the opportunity to expand the application of its Nu.Q platform to detect a wider range of cancer types. The global cancer diagnostics market is estimated to be worth billions of dollars, and early detection is crucial for improving patient outcomes. By broadening the scope of Nu.Q, VolitionRx can capture a larger share of this market and establish itself as a leader in cancer diagnostics.
- Commercialization of Nu.Q Vet: The veterinary diagnostics market represents a significant growth opportunity for VolitionRx. Nu.Q Vet offers a non-invasive and cost-effective solution for cancer screening in animals. As pet ownership continues to rise and pet owners become more willing to invest in their pets' health, the demand for veterinary diagnostics is expected to increase. VolitionRx can capitalize on this trend by expanding the commercialization of Nu.Q Vet through partnerships with veterinary clinics and distributors.
- Development of Nu.Q Nets for immune system monitoring: Nu.Q Nets has the potential to become a valuable tool for monitoring the immune system in various diseases. The global immune monitoring market is growing rapidly, driven by the increasing prevalence of autoimmune diseases and the development of new immunotherapies. VolitionRx can leverage its expertise in nucleosomics to develop Nu.Q Nets into a comprehensive solution for immune system monitoring, capturing a share of this expanding market.
- Strategic partnerships with pharmaceutical companies: Collaborating with pharmaceutical companies can accelerate the development and commercialization of VolitionRx's diagnostic products. Pharmaceutical companies are increasingly seeking diagnostic tools to identify patients who are most likely to respond to their therapies. By partnering with these companies, VolitionRx can gain access to valuable resources and expertise, as well as expand its market reach.
- Geographic expansion into emerging markets: Emerging markets, such as China and India, represent significant growth opportunities for VolitionRx. These markets have large populations and increasing healthcare spending. By expanding its geographic presence into these markets, VolitionRx can tap into a new customer base and drive revenue growth. This expansion could involve establishing local partnerships, obtaining regulatory approvals, and adapting its products to meet the specific needs of these markets.
Opportunities
- Expansion into new cancer types.
- Strategic partnerships with pharmaceutical companies.
- Geographic expansion into emerging markets.
- Development of new diagnostic applications.
Threats
- Competition from established diagnostic companies.
- Regulatory hurdles for new diagnostic tests.
- Potential for technological obsolescence.
- Dependence on funding for research and development.
Competitive Advantages
- Proprietary Nucleosomics technology platform.
- Patents protecting Nu.Q and related products.
- First-mover advantage in the epigenetics-based diagnostics market.
- Growing body of clinical data supporting the accuracy and effectiveness of Nu.Q.
About
VolitionRx Limited, established as a multi-national epigenetics company, is dedicated to the development and commercialization of innovative blood tests designed to diagnose a wide spectrum of cancers and other debilitating diseases. The company's core offering, Nu.Q, represents a novel approach to cancer detection, leveraging the power of nucleosomics to identify disease biomarkers in blood samples. Beyond cancer detection, VolitionRx offers Nu.Q Nets for monitoring the immune system's response, Nu.Q Vet, a cancer screening test tailored for veterinary applications, Nu.Q Capture for enhancing diagnostic accuracy through sample concentration, and Nu.Q Discover, a solution for profiling nucleosomes. VolitionRx operates on the Nucleosomics technology platform, a proprietary approach to blood-based diagnostics. This platform forms the foundation for the company's product portfolio, enabling the development of non-invasive and cost-effective diagnostic solutions. Headquartered in Austin, Texas, VolitionRx has strategically positioned itself to capitalize on the growing demand for advanced diagnostic tools in the healthcare industry. The company's focus on epigenetics and nucleosomics distinguishes it from traditional diagnostic approaches, offering the potential for earlier and more accurate disease detection. VolitionRx's commitment to innovation and accessibility underscores its mission to improve patient outcomes through advanced diagnostic solutions.
What They Do
- Develop blood tests for early cancer detection.
- Offer Nu.Q, a platform for detecting cancer biomarkers.
- Provide Nu.Q Nets for monitoring the immune system.
- Offer Nu.Q Vet, a cancer screening test for veterinary use.
- Provide Nu.Q Capture for concentrating samples for more accurate diagnosis.
- Offer Nu.Q Discover, a solution for profiling nucleosomes.
- Operate Nucleosomics, a technology platform for blood tests.
Business Model
- Develop and sell diagnostic blood tests.
- Generate revenue through direct sales of Nu.Q products.
- Establish partnerships with veterinary clinics and distributors for Nu.Q Vet.
- Potentially license technology to pharmaceutical companies.
Industry Context
VolitionRx operates within the medical diagnostics and research industry, a sector characterized by rapid innovation and increasing demand for early and accurate disease detection. The global diagnostics market is projected to reach billions of dollars in the coming years, driven by factors such as an aging population, rising prevalence of chronic diseases, and advancements in diagnostic technologies. VolitionRx's focus on epigenetics and nucleosomics positions it within a niche segment of the market with significant growth potential. Competitors include companies like ALGS (Algenesis), BDSX (Biodesix), CTSO (Cytosorbents), INMB (Inmune Bio), and MDCX (MediciNova), each with their own diagnostic approaches and target markets.
Key Customers
- Hospitals and clinics seeking early cancer detection tools.
- Veterinary clinics and pet owners looking for cancer screening tests for animals.
- Research institutions studying epigenetics and nucleosomics.
- Pharmaceutical companies developing targeted therapies.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $627,277 | -$5M | $-0.05 |
| Q2 2025 | $406,688 | -$6M | $-0.06 |
| Q1 2025 | $246,385 | -$5M | $-0.06 |
| Q4 2024 | $191,657 | -$6M | $-0.07 |
Source: Company filings
Chart & Info
Price Chart
VolitionRx Limited (VNRX) stock price: $0.20 (+0.00, +0.00%)
Why Bull
- •VNRX insiders seem to be positioning themselves for potential upside, which often signals confidence in the company's future prospects.
- •The buzz in the community suggests there's growing excitement around VNRX's new strategic partnerships, hinting at expanded market reach.
- •Recent positive developments in their core market are fueling optimism about VNRX's ability to capitalize on emerging opportunities.
- •The general market perception is shifting positively, with VNRX being viewed as a potential disruptor in its sector.
Why Bear
- •Insider activity, while sometimes positive, can be misleading; maybe they're just diversifying their holdings, not necessarily a bullish signal.
- •Community sentiment can be fickle; hype doesn't always translate to real-world results, and the excitement might be overblown.
- •While there are positive developments, VNRX might face challenges scaling up and maintaining momentum in a competitive landscape.
- •Market perception can quickly change; negative news or unforeseen events could easily reverse the current positive sentiment surrounding VNRX.
Latest News
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Jan 27, 2026
-
Earnings Scheduled For November 13, 2025
benzinga · Nov 13, 2025
-
12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga · Jul 7, 2025
-
Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
benzinga · Sep 22, 2023
Technical Analysis
Rationale
AI-generated technical analysis for VNRX including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss VolitionRx Limited (VNRX) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for VNRX.
Make a Prediction
Set your price target for VolitionRx Limited (VNRX), choose a timeframe, and track your prediction accuracy.
Current price: $0.20
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VNRX.
Price Targets
Wall Street price target analysis for VNRX.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 8/100
Revenue grew 59.1% YoY, showing strong top-line momentum well above industry average.
-
Gross Margin 10/100
Gross margin of 100.0% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 6/100
Revenue growth is driving operating leverage, meaning profits can grow faster than costs.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates VNRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Earnings Scheduled For November 13, 2025
12 Health Care Stocks Moving In Monday's Pre-Market Session
Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Frequently Asked Questions
What does VolitionRx Limited do?
VolitionRx Limited is an epigenetics company focused on developing and commercializing blood tests for the early detection of cancer and other diseases. Their core technology, the Nu.Q platform, detects cancer biomarkers in blood samples, offering a non-invasive and cost-effective alternative to traditional diagnostic methods. The company's product portfolio includes Nu.Q Vet for veterinary applications and Nu.Q Nets for monitoring the immune system. VolitionRx aims to improve patient outcomes by providing accessible and accurate diagnostic solutions, positioning itself as a leader in the emerging field of epigenetics-based diagnostics.
Is VNRX stock a good buy?
VNRX stock presents a speculative investment opportunity with high potential reward but also significant risk. The company's innovative Nu.Q platform and focus on early cancer detection are promising, but its lack of profitability and high beta indicate volatility. Investors should carefully consider the company's growth prospects, regulatory hurdles, and competitive landscape before investing. While the 100.0% gross margin suggests potential for profitability as revenue scales, the company's current market capitalization of $0.02B reflects its early stage of development. A balanced approach is warranted, considering both the potential upside and the inherent risks.
What are the main risks for VNRX?
VolitionRx faces several key risks, including competition from established diagnostic companies with greater resources, regulatory hurdles and delays in obtaining approvals for new products, and the potential failure to achieve commercial success with Nu.Q. The company's dependence on securing additional funding to support research and development also poses a risk. Additionally, the company's high beta of 1.30 indicates higher volatility compared to the market. These risks could significantly impact the company's financial performance and future prospects. Investors should carefully assess these risks before investing in VNRX.
Is VNRX a good stock to buy?
Whether VNRX is a good investment depends on your financial goals, risk tolerance, and investment horizon. Review the Investment Thesis, SWOT analysis, and Risk sections on this page. Always do your own research and consult a financial advisor before investing.
What is the VNRX MoonshotScore?
MoonshotScore is our proprietary AI-powered rating system that evaluates stocks based on growth potential, financial health, market momentum, and risk factors. It helps investors quickly identify high-potential opportunities. Check the MoonshotScore badge on this page for the current rating.
How often is VNRX data updated?
Stock prices are updated in real-time during market hours (9:30 AM - 4:00 PM ET). Company fundamentals, analyst ratings, and AI insights are refreshed daily. News is updated continuously throughout the day.
What are the growth catalysts for VNRX?
Growth catalysts vary by company and may include new product launches, market expansion, earnings surprises, partnerships, or industry tailwinds. Check the Catalysts section on this page for specific drivers relevant to VolitionRx Limited.
Who are VNRX's main competitors?
VolitionRx Limited's competitors depend on its industry and market segments. Check the Competitors section on this page for a list of direct competitors and how VNRX compares.
What do analysts say about VNRX?
Analyst ratings and price targets for VNRX are aggregated from multiple sources. Check the Analyst Consensus tab for buy/hold/sell ratings and the current consensus price target.
What is VNRX's market cap?
Market capitalization reflects the total market value of VNRX's outstanding shares. Check the Key Statistics section at the top of this page for the current market cap and other key financial metrics.
How has VNRX stock performed recently?
Check the Chart & Info tab for VNRX's recent price action, including daily, weekly, and monthly performance charts with technical indicators.
What are the risks of investing in VNRX?
Every stock carries risk. Check the Risks and Weaknesses sections on this page for VNRX-specific risk factors. Consider macroeconomic conditions, industry trends, and company-specific challenges.
Are insiders buying or selling VNRX?
Insider activity can signal management confidence. Check the Insider Flow tab for recent insider buys, sells, and exercise transactions for VNRX.
Is VNRX a good stock for beginners?
VolitionRx Limited (VNRX) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is VNRX for first-time investors?
Every stock carries risk, including VolitionRx Limited (VNRX). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like VNRX.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Financial data may be outdated.
- Future performance is subject to market conditions and company-specific factors.